Special Issue "Marine Natural Products and Cardiovascular Disease Prevention"
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (30 November 2019).
Interests: algal metabolites; drug discovery; enzyme inhibitors; functional foods; marine and plant natural products; molecular pharmacology of natural products
Interests: marine medicinal bioresources; natural product chemistry; drug discovery
Special Issues and Collections in MDPI journals
Cardiovascular disease (CVD) is a leading cause of death worldwide, which involves devastating dysfunctions of the heart (cardiac) and the blood vessels (vascular). CVD includes atherosclerosis, hypertension, cardiac hypertrophy, heart failure, arrhythmia, ischemic stroke, and coronary heart disease. The development of CVD is the result of complex interactions between different cell types and processes, such as genetic and epigenetic mechanisms, nutritional status, and environmental factors. The residual cardiovascular risk remains very high despite the clinical use of anti-CVD drugs, such as lipid-lowering statins. This scenario highlights the urgent need to identify novel therapeutic agents for treating CVD. With the development of biotechnology, pharmacology, and chemical biology, continued efforts are geared towards the discovery of new drugs or the reposition of currently FDA-approved drugs for CVD therapy. Numerous studies have indicated that marine natural products are one of the most important sources of lead compounds in drug discovery for their natural origin, multiple bioactivities, and relatively high safety profile. Studies in the past decade have indicated that several marine-derived natural products represent an underexplored reservoir for the discovery of cardiovascular lead drugs with unique scaffolds and potential exploitation in the pharmaceutical industry. They also exhibit a wide variety of biological activities against CVD, such as anti-oxidant, lipid-lowering, hypoglycemic, vasodilation, anticoagulation, anti-platelet activation, thrombin inhibition, ion channel-, receptor-, enzyme-blocking activities and anti-inflammatory effects. This Special Issue is proposed to facilitate the translation of marine-derived natural products into pre-clinical or clinical trials.
We herewith invite you to participate in this Special Issue by contributing original research papers, review articles (both long reviews and mini-reviews), and technical notes relevant to the described topic.
Dr. Kannan RR Rengasamy
Dr. Suowen Xu
Prof. Dr. Chang-Yun Wang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- enzyme inhibitors
- type 2 diabetes
- marine natural products
- microbial cardiac infections